133 related articles for article (PubMed ID: 28736245)
1. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract][Full Text] [Related]
2. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
[TBL] [Abstract][Full Text] [Related]
4. Granting immunity to FOP and catching heterotopic ossification in the Act.
Kaplan FS; Pignolo RJ; Shore EM
Semin Cell Dev Biol; 2016 Jan; 49():30-6. PubMed ID: 26706149
[TBL] [Abstract][Full Text] [Related]
5. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Gao P; Inada Y; Hotta A; Sakurai H; Ikeya M
Stem Cell Res Ther; 2024 Mar; 15(1):83. PubMed ID: 38500216
[TBL] [Abstract][Full Text] [Related]
6. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease.
Akyuz G; Gencer-Atalay K; Ata P
Curr Opin Pediatr; 2019 Dec; 31(6):716-722. PubMed ID: 31693578
[TBL] [Abstract][Full Text] [Related]
7. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
[TBL] [Abstract][Full Text] [Related]
8. [Recommendations for the healthcare of patients with FOP].
Seefried L; Banholzer D; Fischer R; Grafe I; Hüning I; Morhart R; Oheim R; Semler O; Siggelkow H; Stockklausner C; Hoyer-Kuhn H
Orthopadie (Heidelb); 2023 Nov; 52(11):924-930. PubMed ID: 37603129
[TBL] [Abstract][Full Text] [Related]
9. Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva.
Burdick LN; DelVichio AH; Hanson LR; Griffith BB; Bouchard KR; Hunter JW; Goldhamer DJ
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397414
[TBL] [Abstract][Full Text] [Related]
10. ACVR1-activating mutation causes neuropathic pain and sensory neuron hyperexcitability in humans.
Yu X; Ton AN; Niu Z; Morales BM; Chen J; Braz J; Lai MH; Barruet E; Liu H; Cheung K; Ali S; Chan T; Bigay K; Ho J; Nikolli I; Hansberry S; Wentworth K; Kriegstein A; Basbaum A; Hsiao EC
Pain; 2023 Jan; 164(1):43-58. PubMed ID: 35442931
[TBL] [Abstract][Full Text] [Related]
11. Cell Senescence in Heterotopic Ossification.
Pignolo RJ; Kaplan FS; Wang H
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672501
[TBL] [Abstract][Full Text] [Related]
12. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
[TBL] [Abstract][Full Text] [Related]
13. Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.
Diolintzi A; Pervin MS; Hsiao EC
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540775
[TBL] [Abstract][Full Text] [Related]
14. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
15. BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
Yu PB; Deng DY; Lai CS; Hong CC; Cuny GD; Bouxsein ML; Hong DW; McManus PM; Katagiri T; Sachidanandan C; Kamiya N; Fukuda T; Mishina Y; Peterson RT; Bloch KD
Nat Med; 2008 Dec; 14(12):1363-9. PubMed ID: 19029982
[TBL] [Abstract][Full Text] [Related]
16. The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification.
Wang H; Kaplan FS; Pignolo RJ
Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397384
[TBL] [Abstract][Full Text] [Related]
17. Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva.
Nikishina IP; Arsenyeva SV; Matkava VG; Arefieva AN; Kaleda MI; Smirnov AV; Blank LM; Kostik MM
Pediatr Rheumatol Online J; 2023 Aug; 21(1):92. PubMed ID: 37644581
[TBL] [Abstract][Full Text] [Related]
18. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.
Pacifici M
Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842
[TBL] [Abstract][Full Text] [Related]
19. Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva.
Sun L; Jin Y; Nishio M; Watanabe M; Kamakura T; Nagata S; Fukuda M; Maekawa H; Kawai S; Yamamoto T; Toguchida J
Life Sci Alliance; 2024 May; 7(5):. PubMed ID: 38365425
[TBL] [Abstract][Full Text] [Related]
20. Long term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.
Haviv R; Zeitlin L; Moshe V; Ziv A; Rabinowicz N; De Benedetti F; Prencipe G; Matteo V; De Cunto CL; Hsiao EC; Uziel Y
Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38733591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
